EP300 and plasma cell myeloma: Despite these concerns, we observed that, while HAT inhibition was superior to bromodomain inhibition in B-lineage acute lymphoblastic leukemias, several tumor types, including endometrial carcinoma, multiple myeloma and medulloblastoma demonstrated enhanced effects with EP300/CBP bromodomain inhibition.